Dr. Reddy's Laboratories Likely Impacted by Short-Term Margin Headwinds -- Market Talk
Dow Jones
May 12
0659 GMT - Dr. Reddy's Laboratories has likely been impacted by short-term margin headwinds, Axis Securities analysts say in a research report as they downgrade the stock's rating to hold from buy and lower the target price to INR1,250.00 from INR1,450.00. The Indian pharmaceutical company's gross margins fell sharply in 4Q FY25 mainly due to costs related to manufacturing overheads, the analysts note. Its North American operations also saw muted growth owing to pricing pressure and lower sales of select products. Moreover, an expected decline in sales of its gRevlimid drug poses short-term headwinds, the analysts add. Shares are 2.5% higher at INR1,185.35. (ronnie.harui@wsj.com)
(END) Dow Jones Newswires
May 12, 2025 02:59 ET (06:59 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.